Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 14

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 14
---
. If we fail to identify, attract, retain and motivate
these highly skilled personnel, we may be unable to continue our product development and commercialization activities.

In addition, biotechnology
and pharmaceutical industries are subject to rapid and significant technological change. Our drug candidates may be or become uncompetitive.
To remain competitive, we must employ and retain suitably qualified staff that are continuously educated to keep pace with changing technology
but may not be in a position to do so.

We may encounter difficulties in managing our growth, which could
negatively impact our operations.

As we advance our clinical
development programs for drug candidates, seek regulatory approval in the United States and elsewhere and increase the number of ongoing
product development programs, we anticipate that we will need to increase our product development, scientific and administrative headcount.
We will also need to establish commercial capabilities in order to commercialize any drug candidates that may be approved. Such an evolution
may impact our strategic focus and our deployment and allocation of resources.

Our ability to manage our
operations and growth effectively depends upon the continual improvement of our procedures, reporting systems and operational, financial
and management controls. We may not be able to implement administrative and operational improvements in an efficient or timely manner
and may discover deficiencies in existing systems and controls. If we do not meet these challenges, we may be unable to execute our business
strategies and may be forced to expend more resources than anticipated addressing these issues.

We may acquire additional
technology and complementary businesses in the future. Acquisitions involve many risks, any of which could materially harm our business,
including the diversion of management’s attention from core business concerns, failure to effectively exploit acquired technologies,
failure to successfully integrate the acquired business or realize expected synergies or the loss of key employees from either our business
or the acquired businesses.

In addition, in order to continue
to meet our obligations as a publicly listed company in both Australia and the United States and to support our anticipated long-term
growth, we will need to increase our general and administrative capabilities. Our management, personnel and systems may not be adequate
to support this future growth.

If we are unable to successfully
manage our growth and the increased complexity of our operations, our business, financial position, results of operations and prospects
may be harmed.

Future potential sales of our drug candidates may suffer if they
are not accepted in the marketplace by physicians, patients and the medical community

There is a risk that our drug
candidates may not gain market acceptance among physicians, patients and the medical community